BACKGROUND: Neutrophil gelatinase-associated lipocalin (NGAL) is a multi-potent 25-kDa protein mainly secreted by neutrophils. In inflammatory bowel disease (IBD), overexpression of NGAL in colon epithelium has been previously shown. This is the first study analyzing serum and urinary NGAL levels in IBD patients, with regard to specific characteristics of patients and disease. METHODS: Serum and urinary NGAL levels were determined in 181 patients with IBD, 93 with ulcerative colitis (UC), and 88 with Crohn's disease (CD), 82 healthy controls (HC), and 41 patients with irritable bowel syndrome (IBS). RESULTS: Serum NGAL levels were elevated in IBD patients (88.19 ± 40.75 ng/mL) compared with either HC (60.06 ± 24.18 ng/mL) or IBS patients (60.80 ± 20.30 ng/mL), P < 0.0001. No significant difference was shown between UC (86.62 ± 35.40 ng/mL) and CD (89.92 ± 46.05 ng/mL). Significantly higher levels of serum NGAL were observed in patients with active (120.1 ± 38.46) versus inactive IBD (61.58 ± 15.98), P < 0.0001. Serum NGAL displayed a strong ability to distinguish active IBD from inactive disease, healthy controls, or IBS patients with a sensitivity of 100, 95, and 95% and a specificity of 68, 83, and 79%, respectively, performing better than erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in the assessment of disease activity in both UC and CD. Urinary NGAL levels showed neither significant difference among patients and controls nor correlation with disease activity. CONCLUSIONS: Serum NGAL is elevated particularly in active IBD and correlates with established markers of inflammation and disease activity, implicating its role in the pathophysiology of IBD.
BACKGROUND:Neutrophil gelatinase-associated lipocalin (NGAL) is a multi-potent 25-kDa protein mainly secreted by neutrophils. In inflammatory bowel disease (IBD), overexpression of NGAL in colon epithelium has been previously shown. This is the first study analyzing serum and urinary NGAL levels in IBD patients, with regard to specific characteristics of patients and disease. METHODS: Serum and urinary NGAL levels were determined in 181 patients with IBD, 93 with ulcerative colitis (UC), and 88 with Crohn's disease (CD), 82 healthy controls (HC), and 41 patients with irritable bowel syndrome (IBS). RESULTS: Serum NGAL levels were elevated in IBD patients (88.19 ± 40.75 ng/mL) compared with either HC (60.06 ± 24.18 ng/mL) or IBSpatients (60.80 ± 20.30 ng/mL), P < 0.0001. No significant difference was shown between UC (86.62 ± 35.40 ng/mL) and CD (89.92 ± 46.05 ng/mL). Significantly higher levels of serum NGAL were observed in patients with active (120.1 ± 38.46) versus inactive IBD (61.58 ± 15.98), P < 0.0001. Serum NGAL displayed a strong ability to distinguish active IBD from inactive disease, healthy controls, or IBSpatients with a sensitivity of 100, 95, and 95% and a specificity of 68, 83, and 79%, respectively, performing better than erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in the assessment of disease activity in both UC and CD. Urinary NGAL levels showed neither significant difference among patients and controls nor correlation with disease activity. CONCLUSIONS: Serum NGAL is elevated particularly in active IBD and correlates with established markers of inflammation and disease activity, implicating its role in the pathophysiology of IBD.
Authors: Subhankar Chakraborty; Sukhwinder Kaur; Venkata Muddana; Neil Sharma; Uwe A Wittel; Georgios I Papachristou; David Whitcomb; Randall E Brand; Surinder K Batra Journal: Am J Gastroenterol Date: 2010-02-23 Impact factor: 10.864
Authors: De-xiu Bu; Anne-Louise Hemdahl; Anders Gabrielsen; Jonas Fuxe; Chaoyong Zhu; Per Eriksson; Zhong-qun Yan Journal: Am J Pathol Date: 2006-12 Impact factor: 4.307
Authors: Alain M Schoepfer; Christoph Beglinger; Alex Straumann; Michael Trummler; Stephan R Vavricka; Lukas E Bruegger; Frank Seibold Journal: Am J Gastroenterol Date: 2009-09-15 Impact factor: 10.864
Authors: Davide Bolignano; Anna Della Torre; Antonio Lacquaniti; Giuseppe Costantino; Walter Fries; Michele Buemi Journal: J Investig Med Date: 2010-03 Impact factor: 2.895
Authors: J Malyszko; J S Malyszko; H Bachorzewska-Gajewska; B Poniatowski; S Dobrzycki; M Mysliwiec Journal: Transplant Proc Date: 2009 Jan-Feb Impact factor: 1.066
Authors: Guus A M Kortman; Michelle L M Mulder; Thijs J W Richters; Nanda K N Shanmugam; Estela Trebicka; Jos Boekhorst; Harro M Timmerman; Rian Roelofs; Erwin T Wiegerinck; Coby M Laarakkers; Dorine W Swinkels; Albert Bolhuis; Bobby J Cherayil; Harold Tjalsma Journal: Eur J Immunol Date: 2015-06-23 Impact factor: 5.532
Authors: Mei San Tang; Rowann Bowcutt; Jacqueline M Leung; Martin J Wolff; Uma M Gundra; David Hudesman; Lisa B Malter; Michael A Poles; Lea Ann Chen; Zhiheng Pei; Antonio G Neto; Wasif M Abidi; Thomas Ullman; Lloyd Mayer; Richard A Bonneau; Ilseung Cho; Pʼng Loke Journal: Inflamm Bowel Dis Date: 2017-09 Impact factor: 5.325
Authors: Kristyn Gumpper; Andrew William Dangel; Valentina Pita-Grisanti; Somashekar G Krishna; Luis F Lara; Thomas Mace; Georgios I Papachristou; Darwin L Conwell; Phil A Hart; Zobeida Cruz-Monserrate Journal: Pancreatology Date: 2020-01-07 Impact factor: 3.996
Authors: Mehmet Odabasi; Atakan Yesil; Selvinaz Ozkara; Nurcan Paker; Sevil Ozkan; Cengiz Eris; Mehmet Kamil Yildiz; Hacı Hasan Abuoglu; Emre Gunay; Kemal Tekeşin Journal: Int J Clin Exp Med Date: 2014-09-15
Authors: A E Østvik; A V B Granlund; S H Torp; A Flatberg; V Beisvåg; H L Waldum; T H Flo; T Espevik; J K Damås; A K Sandvik Journal: Clin Exp Immunol Date: 2013-09 Impact factor: 4.330